The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Gong, Jun; Chehrazi-Raffle, Alexander; Placencio-Hickok, Veronica; Guan, Michelle; Hendifar, Andrew; Salgia, Ravi

Gong, Jun; Chehrazi-Raffle, Alexander; Placencio-Hickok, Veronica; Guan, Michelle; Hendifar, Andrew; Salgia, Ravi.

Afiliación

Gong J; Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Chehrazi-Raffle A; Department of Internal Medicine, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA, 90509, USA.
Placencio-Hickok V; Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Guan M; Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Hendifar A; Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Salgia R; Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Building 51, Room 101, 1500 E Duarte St, Duarte, CA, 91010, USA. rsalgia@coh.org.

Clin Transl Med ; 8(1): 9, 2019 Mar 18.

Article en En | MEDLINE | ID: mdl-30887236

Palabras clave

Biomarkers; CTLA-4; Commensal bacteria; Gut microbiome; Immune checkpoint inhibitors; PD-1; PD-L1

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Transl Med Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google